Shares of Dermira (NASDAQ:DERM) saw an erosion of -0.2 points in recent session. During the trading, the value of each share was $30.07, dropping -0.66%. The shares saw high fund-flow as the composite value of all the upticks was $1.29 million and the total value of all the downticks was a mere $0.67 million. The net money flow was seen at $0.62 million and the up/down ratio was measured at 1.92. On a weekly basis the shares of the shares have recorded a change of -0.86%.The block trade which occurred today had $0.55 million in upticks and $0 million in downticks with the up/down ratio climbing to 0. $0.55 million was the net money flow of the block transaction.
Currently the company Insiders own 19.2% of Dermira shares according to the proxy statements. Institutional Investors own 74.34% of Dermira shares. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Wiggans Thomas G, (CEO & Chairman of the Board) of Dermira, Inc., had unloaded 11,000 shares at an average price of $31.34 in a transaction dated on June 1, 2016. The total value of the transaction was worth $344,740.
Dermira (NASDAQ:DERM) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.4 points or 1.32% at $29.87 with 362,074 shares getting traded. Post opening the session at $30.34, the shares hit an intraday low of $29.78 and an intraday high of $30.85 and the price was in this range throughout the day. The company has a market cap of $897 million and the number of outstanding shares have been calculated to be 30,018,641 shares. The 52-week high of Dermira (NASDAQ:DERM) is $35.75 and the 52-week low is $15.56.
Many analysts have stated their opinion on the company shares. Citigroup maintains its rating on Dermira (NASDAQ:DERM). The global brokerage major lowers the current price target from $42 per share to $40 per share. Analysts at the Citigroup have a current rating of Buy on the shares. The rating by the firm was issued on March 16, 2016.
Dermira, Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Companys portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol), which the Company is developing in collaboration with UCB Pharma S.A. (UCB), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical, small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical, small-molecule sebum inhibitor the Company is developing for the treatment of acne.